Anhco Nguyen
Hoofd Techniek/Wetenschap/O&O bij ATARA BIOTHERAPEUTICS, INC.
Vermogen: 628 949 $ op 30-04-2024
Actieve functies van Anhco Nguyen
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 10-05-2021 | - |
Loopbaan van Anhco Nguyen
Eerdere bekende functies van Anhco Nguyen
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ENUMERAL BIOMEDICAL HOLDINGS INC | Hoofd Techniek/Wetenschap/O&O | 04-08-2014 | 17-08-2016 |
| Massachusetts Institute of Technology | Corporate Officer/Principal | - | - |
| FATE THERAPEUTICS, INC. | Corporate Officer/Principal | - | - |
Opleiding van Anhco Nguyen
| University of Washington | Doctorate Degree |
| Harvard College | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 7 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
| Finance | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Enumeral Biomedical Holdings, Inc.
 Enumeral Biomedical Holdings, Inc. BiotechnologyHealth Technology Enumeral Biomedical Holdings, Inc. is a biopharmaceutical company, which engages in the business of discovering and developing novel antibody immunotherapies for the treatment of cancer and other diseases. It also focuses on the development of a pipeline of next generation monoclonal antibody drugs targeting established and novel immuno-modulatory receptors. The company was founded by Barry C. Buckland, John J. Rydzewski, and Arthur H. Tinkelenberg on December 11, 2009 and is headquartered in Arlington, MA. | Health Technology |
- Beurs
- Insiders
- Anhco Nguyen
- Ervaring
